CLYD, the key deubiquitinating enzyme in the apoptosis/necroptosis pathway, is directly targeted by miR-181b-1 and miR-19 in cancer cells, causing the hyperactivation of the NF-κB signaling pathway, increased inflammation and tumor progression [148,149]. Here, NFKB1 is linked to neoplasm.